Sugi Predict

Sugi Predict / Compounds / SCHEMBL2016642

SCHEMBL2016642

SCHEMBL2016642

OC1(c2ccc(OCc3ccccc3)cc2)CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 11/20 0.53
▸ HRH3 Q9Y5N1 1/20 0.52
▸ LMNA P02545 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ SLC6A2 P23975 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ MMP1 P03956 1/20 0.50
▸ MMP13 P45452 1/20 0.50
▸ GAA P10253 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ NR4A1 P22736 1/20 0.46
▸ NR4A2 P43354 1/20 0.46
▸ NR4A3 Q92570 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9221360 0.88 ALOX5 (0.53) ALOX5KMT2AALDH1A1
SCHEMBL16553890 0.86 LMNA (0.56) HRH3LMNACYP1A2PTGS1SLC6A2
SCHEMBL9229060 0.85 ALOX5 (0.70) ALOX5HRH3
SCHEMBL10041856 0.85 LMNA (0.54) HRH3LMNACYP1A2PTGS1SLC6A2
SCHEMBL16179215 0.85 LMNA (0.54) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL17072362 0.85 LMNA (0.54) HRH3LMNACYP1A2PTGS1SLC6A2
SCHEMBL9217663 0.85 ALOX5 (0.61) ALOX5ALDH1A1
SCHEMBL5690507 0.85 LMNA (0.47) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL8551875 0.82 ALOX5 (0.59) ALOX5PTGS1PTGS2
SCHEMBL9966397 0.82 MAOB (0.50) ALOX5LMNACYP1A2PTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
US-11492358-B1 Macrocyclic indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-11-08 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 — — EP disclosed
CN-109715632-B Macrocyclic indole derivatives 拜尔公开股份有限公司 2021-10-26 — — CN disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
US-20110160180-A1 Cannabinoid Receptor Ligands ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
EP-2190838-A1 CANNABINOID RECEPTOR LIGANDS AstraZeneca AB (SE) 2010-06-02 — — EP disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
US-20090062251-A1 Novel Compounds 002 ASTRAZENECA AB (SE) 2009-03-05 — — US disclosed
WO-2009024819-A1 CANNABINOID RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
WO-2009024819-A1 CANNABINOID RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
US-6713508-B2 SUCH AS 7-(3-(3-TRIFLUOROMETHYL-7-PROPYL-6-BENZ-(4,5)-ISOXAZOLOXY)PROPOXY)-2 -ETHYLCHROMANE-2-CARBOXYLIC ACID WHICH ARE POTENT AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MERCK & CO., INC. 2004-03-30 — — US disclosed
US-20020103242-A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders MERCK SHARP & DOHME CORP. 2002-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103242-A1 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders PPARD, PPARA, PPARG ALOX5 656/4885HRH3 2103/4885LMNA 3810/4885
US-20090062251-A1 Novel Compounds 002 OPRL1, OPRK1, OPRM1 ALOX5 1939/4885HRH3 696/4885LMNA 4238/4885
US-20110160180-A1 Cannabinoid Receptor Ligands CNR1, CNR2, OPRL1 ALOX5 1093/4885HRH3 201/4885LMNA 3820/4885
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR ALOX5 1793/4885HRH3 2402/4885LMNA 81/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT ALOX5 188/4885HRH3 3323/4885LMNA 2434/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT ALOX5 188/4885HRH3 3323/4885LMNA 2434/4885
US-11492358-B1 Macrocyclic indole derivatives CCND2, CCNT2, IDO1 ALOX5 1436/4885HRH3 104/4885LMNA 962/4885
US-10981932-B2 Macrocyclic indole derivatives CCND2, IDO1, CCNT2 ALOX5 1492/4885HRH3 95/4885LMNA 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.